Spyre Therapeutics (SYRE) CFO Burrows sold 7,500 shares for $658K at an average $87.74 under a 10b5-1 plan
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Scott L Burrows (Chief Financial Officer at Spyre Therapeutics Inc., SYRE) reported that they sold 7,500 shares for $658K at an average $87.74, and acquired 7,500 shares at $14.50 on Jul 1, 2026. After these transactions the filing shows 97,994 shares held directly.
- Reporting person
- Burrows Scott L
- Role
- Chief Financial Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +7,500 | $14.50 | $109K | 105,494 direct |
| Jul 1, 2026 | Open-market sale (S) | Common Stock1, 2, 3, ... | -7,500 | avg $87.74 | $658K | 97,994 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 7,500 Common Stock1, 5 | -7,500 | - | - | 352,357 direct |
Holdings before and after
- Stock Option (Right to Buy): 359,857 to 352,357 direct
Footnotes from the filing
- 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- 2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC ), upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. Includes 67,476 restricted stock units ( RSUs ). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- 5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Burrows report in this SYRE Form 4?
Scott L Burrows (Chief Financial Officer at Spyre Therapeutics Inc., SYRE) reported that they sold 7,500 shares for $658K at an average $87.74, and acquired 7,500 shares at $14.50 on Jul 1, 2026. After these transactions the filing shows 97,994 shares held directly.
How many SYRE shares does Burrows hold after this filing?
The filing shows 97,994 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this SYRE insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for SYRE
Across the 27 sessions after earlier SYRE headlines, the stock closed higher 21 times and lower 6 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SYRE | SPY |
|---|---|---|---|
| Jul 6, 2026 | Spyre Therapeutics Announces Grants of Inducement Awards | +2.4% | +0.9% |
| Jun 15, 2026 | Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients | +3.5% | +1.8% |
| Jun 8, 2026 | Spyre Therapeutics Announces Grants of Inducement Awards | -2.2% | +0.2% |
| Jun 3, 2026 | Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA | +6.3% | -0.7% |
| May 27, 2026 | Spyre Therapeutics to Participate in Upcoming June Investor Conferences | -1.5% | -0.0% |
| May 5, 2026 | Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | +2.7% | +0.8% |
Earlier insider filings at SYRE
- Jul 3, 2026Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 3, 2026Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)
- Jun 27, 2026Chief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)
- Jun 24, 2026Director Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)
- Jun 24, 2026Director Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)
Keep researching SYRE
- SYRE insider tradesEvery buy and sale reported by Spyre Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- SYRE earnings historyPast Spyre Therapeutics Inc. earnings releases, newest first.
- SYRE financial statementsRevenue, profit, cash flow and balance sheet from Spyre Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
SYRE
Spyre Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Get push alerts for SYRE
Full SYRE profile on Quantisnow Follow SYRE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time